Oral vs Injectable Peptides: What the FDA Labels and SNAC Reviews Report

Peptides Vietnam read the FDA labels for every approved oral and injectable semaglutide product plus both major SNAC reviews, and says so where the evidence runs out.

Why are most peptides not orally active?

The stomach and intestine degrade peptides, and peptide molecules cross the gut wall poorly, so almost none of a swallowed dose reaches circulation.

A 2024 review of SNAC technology in Clinical Diabetes gives the plain explanation: the gastrointestinal environment breaks peptides down and they permeate the gut lining badly (PMID 38230324).

All three authors of that review declare speaker or consultant relationships with Novo Nordisk, the maker of oral semaglutide, which is material for a review broadly favourable to the technology.

A second review in Pharmaceutics, comparing SNAC with the older sodium caprate, reports single digit and highly variable oral bioavailability in human trials with these enhancers (PMID 30781867).

This is why the list of approved oral peptides is so short.

An oral peptide needs a formulation built to protect it and carry it across the gut wall, and even then the yield is small. Our beginner overview of how peptides are used covers the wider route picture.

How much of an oral peptide actually reaches the bloodstream?

For semaglutide, the cleanest natural experiment available, the label figures are 89% by injection against roughly 0.4% to 2% by tablet.

This is the strongest evidence in this cluster: same molecule, same manufacturer, both routes approved.

The Rybelsus label gives approximately 0.4% to 1% bioavailability for the 3, 7 and 14 mg tablets, and the Ozempic tablet label gives 1% to 2% for the 1.5, 4 and 9 mg tablets. Against 89% for the injection, that is roughly a 50 to 200 fold difference.

Peak timing differs too, about 1 hour oral against 1 to 3 days subcutaneous, and the label warns that blood concentrations after the tablet are lower and more variable. It also states the tablet and injection are not substitutable milligram for milligram (see Ozempic versus generic semaglutide).

The approved semaglutide labels specify:

Is subcutaneous absorption a single number?

No. The labels show subcutaneous bioavailability is molecule specific and, for dulaglutide, explicitly dose dependent.

This is the contradiction most comparison pages miss. Semaglutide at 89% supports the impression that injection means near complete delivery.

The Trulicity label breaks it: dulaglutide sits at 65% for the 0.75 mg dose and falls to 47% at 1.5 mg, so under half the injected amount reaches circulation and the fraction drops as the amount rises. Tirzepatide lands between at 80%, with a wide time to peak of 8 to 72 hours.

Any blanket claim that injected peptides are fully absorbed is wrong; the honest version cites the range across named products.

The approved GLP-1 labels specify:

What does the oral semaglutide label require?

The label ties the tablet to a strict fasting routine because its small absorption depends on that routine.

The Rybelsus and Ozempic tablet labels specify an empty stomach, no more than 4 ounces of water, and at least 30 minutes before any food, other drinks or other oral medicines, with the tablet swallowed whole and a missed dose skipped. The dosing section cross references these constraints to clinical pharmacology: they exist because absorption depends on them.

The Rybelsus and Ozempic tablet labels specify:

How does SNAC work, and how certain is the science?

Reviews describe SNAC as raising stomach pH locally, keeping semaglutide in monomer form and inhibiting pepsin, but they also state the mechanism is still debated after 30 years.

The 2024 Clinical Diabetes review describes SNAC as enhancing absorption of semaglutide in the stomach and protecting it from gastric enzymes (PMID 38230324), and as noted above, all three of its authors declare speaker or consultant ties to Novo Nordisk.

The 2019 Pharmaceutics review is more candid (PMID 30781867). It states the mechanism is still debated after 30 plus years of study, that evidence for specific epithelial mechanisms is equivocal at the high doses used in vivo, and that the effects of repeat dosing beyond six months have not been assessed.

That is not evidence of harm. It is an unstudied window.

What about research peptides like BPC-157?

Every quantified oral absorption figure in this evidence base traces to one molecule, semaglutide, paired with SNAC. No trial was located testing oral absorption of any research peptide in humans, so oral claims for compounds like BPC-157 rest on nothing verified here.

Formulation is the other live issue. When compounded tirzepatide combined with vitamin B12 analogues was tested, analysts found a previously unidentified impurity from a chemical reaction between the two (PMID 42010938).

All five authors of that paper are Eli Lilly employees, and Lilly manufactures the approved tirzepatide products the compounded versions compete with, so the finding carries that conflict. The authors state the clinical effects of the impurity are unknown.

The narrow lesson: combining a peptide with other actives changes the chemistry in ways the ingredient list does not reveal. Related reading: spotting fake GLP-1 products in Vietnam and the independent third-party testing labs directory.

What did we check and what did we not find?

For the injectable side, see the guides on how to inject peptides, subcutaneous versus intramuscular injection, insulin syringe sizes and storing peptides in Vietnam heat. The peptide reconstitution calculator handles the volume math for reconstituted injectables. For sourcing, Peptara Labs is our trusted supply partner, and we may earn from purchases made through our links.

What we left out

The Short Version

Frequently Asked Questions

References